^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABM-2752

    i
    Other names: ABM-2752
    Associations

    News

    Trials
    Company:
    ABM Therap
    Drug class:
    HPK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    ABM-2752, a potent and selective HPK1 inhibitor with excellent efficacies as a single agent or in combination with a PD-1 antibody (AACR 2023)
    Preliminary tox studies indicated a good safety window. Based on these preclinical results we plan to file IND in 2023.
    Combination therapy
    |
    IL2 (Interleukin 2) • LCP2 (Lymphocyte cytosolic protein 2)
    |
    ABM-2752